Efficacy of EGb 761 120mg Twice a Day Versus Placebo on Cognitive Impairment in Patients With Multiple Sclerosis. A Randomised, Double-Blind, Multicentre, Parallel Groups Placebo Controlled Phase III Study.

Trial Profile

Efficacy of EGb 761 120mg Twice a Day Versus Placebo on Cognitive Impairment in Patients With Multiple Sclerosis. A Randomised, Double-Blind, Multicentre, Parallel Groups Placebo Controlled Phase III Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2014

At a glance

  • Drugs EGb 761 (Primary)
  • Indications Cognition disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Ipsen
  • Most Recent Events

    • 02 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top